Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 235.92M P/E - EPS this Y 82.40% Ern Qtrly Grth -
Income -20.23M Forward P/E -1.90 EPS next Y -339.30% 50D Avg Chg 13.00%
Sales 81.63M PEG -0.87 EPS past 5Y - 200D Avg Chg -34.00%
Dividend N/A Price/Book 0.80 EPS next 5Y 16.40% 52W High Chg -75.00%
Recommedations 2.70 Quick Ratio 21.84 Shares Outstanding 62.40M 52W Low Chg 70.00%
Insider Own 1.62% ROA -6.89% Shares Float 40.29M Beta 2.24
Inst Own 99.67% ROE -7.37% Shares Shorted/Prior 11.40M/8.15M Price 3.82
Gross Margin 9.02% Profit Margin -24.79% Avg. Volume 720,272 Target Price 5.29
Oper. Margin 65.62% Earnings Date Nov 5 Volume 367,973 Change 2.96%
About Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. It has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies; and Sanofi for the development and commercialization of losmapimod, an oral small molecule being investigated for the treatment of facioscapulohumeral muscular dystrophy. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Fulcrum Therapeutics, Inc. News
12/19/24 Fulcrum Therapeutics (NASDAQ:FULC) shareholders have endured a 77% loss from investing in the stock three years ago
11/28/24 Fulcrum Therapeutics (FULC) Upgraded to Buy: Here's Why
11/26/24 Fulcrum Therapeutics to Participate in Upcoming December Conferences
11/15/24 Fulcrum Therapeutics Third Quarter 2024 Earnings: US$0.35 loss per share (vs US$0.39 loss in 3Q 2023)
11/14/24 Fulcrum Therapeutics Inc (FULC) Q3 2024 Earnings Call Highlights: Strategic Advancements Amidst ...
11/13/24 Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2024
11/12/24 Fulcrum Therapeutics to Participate in the Stifel Healthcare Conference
11/06/24 Fulcrum Therapeutics to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, November 13, 2024 at 8:00 a.m. ET
10/25/24 Fulcrum Before Q3 Earnings: How Should Investors Play the Stock?
09:07 AM We're Interested To See How Fulcrum Therapeutics (NASDAQ:FULC) Uses Its Cash Hoard To Grow
10/18/24 Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up
10/11/24 Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/09/24 Fulcrum Therapeutics Inc (FULC) Q2 2024 Earnings Call Highlights: Strong Financial Performance ...
10/09/24 Fulcrum Stock Tanks 58% in a Month: Buying Opportunity or Risky Bet?
10/07/24 FMR LLC's Strategic Reduction in Fulcrum Therapeutics Inc Shares
10/04/24 Down -57.53% in 4 Weeks, Here's Why Fulcrum Therapeutics (FULC) Looks Ripe for a Turnaround
09/17/24 RA Capital Management's Strategic Acquisition of Fulcrum Therapeutics Shares
09/16/24 Fulcrum Therapeutics (FULC) Loses -65.58% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
09/13/24 FULC Stock Falls as Muscle Disorder Study Misses Primary Goal
09/12/24 Fulcrum Therapeutics Suspends Rare Muscular Disease Candidate After Disappointing Data From Pivotal Trial
FULC Chatroom

User Image Flowjob Posted - 3 days ago

$FULC any news with SCD could send this to double digits easy GL longs!

User Image Mudwalk Posted - 4 days ago

$FULC Is a short squeeze in the works?

User Image Mudwalk Posted - 4 days ago

$FULC When do they release new data? Not sure if this is rising bc of general market or due to anticipation of good news.

User Image Mudwalk Posted - 5 days ago

$FULC This needs favorable news on the SCD pipeline---whole future and stock worth hinges on data. Which given how complex it is, it is bound to fail. I really believe this stock will crash 95% and be in OTC. This company doesn't even have a partnership as of now.

User Image Mudwalk Posted - 1 week ago

$FULC keeps rising and dumping

User Image Drugtrade Posted - 1 week ago

$FULC looks good for at leasta swing, may be long with profits for data $7 target

User Image StockConsultant Posted - 1 week ago

$FULC Fulcrum Therapeutics stock, watch for a bottom breakout above 4.08 at https://stockconsultant.com/?FULC

User Image Mudwalk Posted - 1 week ago

$FULC would we nice if we short squeezed just like old times.

User Image Mudwalk Posted - 1 week ago

$FULC I believe new data on SCD comes out in a few months. If results are somwhat good than this stock has a chance---if results are not good than this stock will plummet and company eventually disappears.

User Image TheMFBearKillla Posted - 2 weeks ago

$FULC Shorty Shortyyyyyyyyyyy IBFB

User Image Mudwalk Posted - 2 weeks ago

$FULC And why did this dump from $4? What's the bad news?

User Image Mudwalk Posted - 2 weeks ago

$FULC resistance is at 4---it touches 4 and crashes to 3.80's

User Image Mudwalk Posted - 11/29/24

$FULC What's going on here?

User Image Mudwalk Posted - 11/27/24

$FULC I sure hope they have good data. That will propel this stock big time----Would be awesome if this stock did a mega pop like old times.

User Image Quantum_Capital_LLC Posted - 11/27/24

$FULC broke through first; $CDNA setup could be next. $LEGN not cooperating despite good technical indicators because volume is not there.

User Image Mudwalk Posted - 11/26/24

$FULC How likely is a return to $11?

User Image Mudwalk Posted - 11/26/24

$FULC What's the next news/data that will make or break this stock play?

User Image Quantum_Capital_LLC Posted - 11/25/24

$CDNA $FULC $LEGN shows improving technical indicators and have good/high potential to continue near term; deserves consideration.

User Image Mudwalk Posted - 11/24/24

$FULC Clearly, this company is hoping on positive outcomes on this SCD med. However, if successful this stock will revisit $10+ and if a failure this company will plummet and cease to exist. With my luck it will plummet and I will lose all my money on this play. And we talk bout a lot of money.

User Image NVDAMillionaire Posted - 11/22/24

$FULC Fulcrum Therapeutics (FULC): Navigating the Rare Disease Landscape with Promising Pipelines https://beyondspx.com/article/fulcrum-therapeutics-fulc-navigating-the-rare-disease-landscape-with-promising-pipelines

User Image Luella_Salinas Posted - 1 month ago

$CRBP $ETON $FULC LFG, expected this to move higher. Also, your thoughts on MYNZ? Who's behind the 30M share offering deal? đź‘€ And how could the Thermo Fisher (TMO) partnership ($210B market cap) reflect this stock movement and PR buzz everywhere on socials?

User Image Mudwalk Posted - 1 month ago

$FULC Holy smokes---we are under 3? What is going on? is this stock in danger? I'm down so much money now. Any hope here.

User Image Mudwalk Posted - 1 month ago

$FULC The question is: Does this company have good things to look forward to? Is the story /outlook good? If so, worth holding onto shares despite recent tute dumping shares.

User Image Mudwalk Posted - 1 month ago

$FULC Yea---This may be the beginning of the end. If the tutes are selling it means that there are no gains to be made. Now I have to decide where I take the big hit or not. This is painful.

User Image Stradella Posted - 1 month ago

$FULC RTW Investments sold all shares: June 30, 2024 they had 9.3% https://finance.yahoo.com/quote/FULC/holders/ Today they filed 0% http://archive.fast-edgar.com/20241114/A42ZF2228222A9ZZ252U2ZOH479VZ222ZC62/

User Image Mudwalk Posted - 1 month ago

$FULC We why did we dip towards the end? Whats going on with this play? Do they have a good story?

User Image Stradella Posted - 1 month ago

$FULC No surprises on the ER, good or bad. Pretty much a nothing burger. 2 cohorts of the trial, with 10 patients in each. Very small, so the data probably will not have significant impact. Now it's a waiting game...

User Image Mudwalk Posted - 1 month ago

$FULC So----we popped to 4 and dumped. Must be some bad news we don't know. I don't get it.

User Image bologniesi Posted - 1 month ago

$FULC Any important news?

User Image DonCorleone77 Posted - 1 month ago

$FULC Fulcrum Therapeutics expects cash to fund operations into at least 2027 Based on its current operating plans, Fulcrum expects to end 2024 with approximately $240.0 million of cash, cash equivalents, and marketable securities, and expects its cash burn for the full year 2025 will be approximately $55.0 million to $65.0 million. Fulcrum also expects that its cash, cash equivalents, and marketable securities as of September 30, 2024 will be sufficient to fund its current operating requirements into at least 2027.

Analyst Ratings
RBC Capital Sector Perform Sep 13, 24
HC Wainwright & Co. Neutral Sep 13, 24
Leerink Partners Market Perform Sep 12, 24
B of A Securities Underperform Sep 12, 24
Stifel Hold Sep 12, 24
Cantor Fitzgerald Neutral Sep 12, 24
B of A Securities Neutral Sep 9, 24
HC Wainwright & Co. Buy Aug 1, 24
Cantor Fitzgerald Overweight Jul 10, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
RA CAPITAL MANAGEMENT, L.P. 10% Owner 10% Owner Jan 20 Buy 13.00 1,923,076 24,999,988 11,609,704 01/24/23
Gould Robert J Interim President &.. Interim President & CEO Jan 13 Sell 15.00 6,766 101,490 499,864 01/13/23
RA CAPITAL MANAGEMENT, L.P. 10% Owner 10% Owner Dec 27 Buy 5.9941 4,089 24,510 9,505,925 12/29/22
Gould Robert J Director Director Jun 07 Option 7.84 71,435 560,050 578,065 06/08/22
Gould Robert J Director Director Jun 07 Sell 8.09 71,435 577,909 506,630 06/08/22
Gould Robert J Director Director Jun 02 Option 7.84 66,622 522,316 531,012 06/06/22
Gould Robert J Director Director Jun 02 Sell 7.99 66,622 532,310 506,630 06/06/22
Gould Robert J Director Director Apr 07 Option 7.84 5,631 44,147 512,261 04/11/22
Gould Robert J Director Director Apr 07 Sell 24.02 5,631 135,257 506,630 04/11/22
Gould Robert J Director Director Apr 01 Option 7.84 94,251 738,928 559,182 04/05/22
Gould Robert J Director Director Apr 01 Sell 24.1 94,251 2,271,449 506,630 04/05/22